Zoetis Inc. (NYSE:ZTS): A Strong Contender in the Animal Health Industry

• Zoetis Inc. (NYSE:ZTS) surpasses Q3 earnings expectations with an adjusted EPS of $1.70.
• Stifel Nicolaus sets a price target of $140 for Zoetis, indicating a potential upside of 11.56%.
• Despite challenges in monoclonal antibody products and livestock product sales, Zoetis maintains a strong market presence in the animal health industry.

Zoetis Inc. (NYSE:ZTS) is a prominent player in the animal health industry, providing a wide range of products and services for pets and livestock. The company is known for its innovative solutions in parasiticides, diagnostics, and dermatology. Zoetis faces competition from other major firms in the sector, but it continues to maintain a strong market presence.

On November 4, 2025, Stifel Nicolaus set a price target of $140 for Zoetis, suggesting a potential upside of about 11.56% from its trading price of approximately $125.50 at the time. This optimistic outlook is supported by Zoetis's strong financial performance in the third quarter of 2025. The company reported an adjusted earnings per share of $1.70, surpassing the consensus estimate of $1.62.

Zoetis's adjusted net income reached $754 million, reflecting a 5% increase on a reported basis and a 9% rise on an organic operational basis. The company's sales amounted to $2.4 billion, a 1% year-over-year increase, although slightly below the expected $2.41 billion. This growth was driven by the success of its parasiticides, diagnostics, and dermatology portfolios.

However, Zoetis faced challenges with its monoclonal antibody products for osteoarthritis pain, such as Librela for dogs and Solensia for cats, which experienced a decline. Additionally, sales of livestock products fell by 9% due to the divestiture of the medicated feed additive product portfolio. Despite these challenges, Zoetis remains focused on its strategic priorities.

The stock for ZTS is currently priced at $126.06, reflecting a decrease of approximately 12.67% from its previous high. The stock has fluctuated between a low of $122.03 and a high of $128.11 today. Zoetis's market capitalization stands at approximately $55.87 billion, with a trading volume of 7,642,200 shares. The company continues to adapt to macroeconomic trends and the operational environment.

Zoetis Inc. (NYSE:ZTS) is a leading global animal health company that develops and manufactures medicines and vaccines for pets and livestock. The company is set to release its third-quarter 2025 earnings on November 4, 2025. Wall Street anticipates earnings per share (EPS) of $1.62 and revenue of approximately $2.41 billion.

Zoetis is expected to surpass these estimates, driven by strong demand for its companion animal products like Simparica Trio and Apoquel. The Zacks Consensus Estimate aligns with Wall Street's projections, suggesting robust performance in the companion animal segment. However, the company may face challenges in its livestock product revenue due to the divestiture of certain assets.

The company's diverse portfolio continues to support its financial health. Zoetis is projected to report a year-over-year increase in earnings, attributed to higher revenues for the quarter ending September 2025. This potential growth could positively impact the stock price, although any shortfall in expectations might lead to a decline.

Zoetis' financial metrics provide insight into its market valuation. With a price-to-earnings (P/E) ratio of 24.60, investors are willing to pay $24.60 for every dollar of earnings. The price-to-sales ratio of 6.82 and enterprise value to sales ratio of 7.39 reflect the market's valuation of its revenue and sales.

The company's financial stability is further highlighted by its debt-to-equity ratio of 1.36, indicating a balanced use of debt and equity in financing. A current ratio of 1.76 suggests Zoetis can comfortably cover its short-term liabilities. The earnings yield of 4.07% offers a return on investment based on earnings, showcasing the company's profitability.

• Zoetis Inc. (NYSE:ZTS) showcases a significant growth potential of 19.01%, indicating the stock might be undervalued.
• The company has a Piotroski Score of 8, reflecting strong financial health and fundamentals.
• Analysts have set a target price of $181.67 for Zoetis, suggesting a potential upside from its current trading levels.

Zoetis Inc. (NYSE:ZTS) is a leading global animal health company, specializing in the discovery, development, and manufacturing of vaccines and medicines for pets and livestock. As a spin-off from Pfizer in 2013, Zoetis has established itself as a key player in the animal health industry, competing with companies like Elanco and Merck Animal Health.

Despite a slight dip of 1.94% over the past 10 days, Zoetis has shown resilience with a monthly gain of 0.55%. This indicates a steady upward trend, reflecting investor confidence and positive market sentiment. The recent decline could present a buying opportunity for investors looking to capitalize on the stock's potential rebound.

Zoetis boasts a significant growth potential of 19.01%, suggesting that the stock is currently undervalued. This makes it an attractive option for growth-oriented investors. The company's strong fundamentals, as indicated by a Piotroski Score of 8, highlight its financial health, including profitability, leverage, liquidity, and operating efficiency.

Analysts have set a target price of $181.67 for Zoetis, reflecting expectations of the stock's fair value. This suggests a potential upside from its current trading levels, making it a compelling investment opportunity. Investors should consider adding ZTS to their portfolios, keeping an eye on market trends and company developments.

• Zoetis Inc. (NYSE:ZTS) is expected to report an EPS of $1.38, marking an 11.3% increase from the previous year.
• Projected revenues for the quarter ending December 2024 are estimated to reach $2.31 billion, a 4.6% rise.
• The company's P/E ratio stands at 32.48, with a debt-to-equity ratio of 1.29, indicating a solid financial position ahead of its earnings report.

Zoetis Inc. (NYSE:ZTS), a leading global animal health company, is gearing up to release its quarterly earnings on February 13, 2025, before the market opens. As a significant player in the veterinary vaccines and medicines sector, Zoetis competes with industry giants like Elanco Animal Health and Merck Animal Health.

Wall Street analysts have set the bar with an earnings per share (EPS) estimate of $1.37 for Zoetis, alongside projected revenues of approximately $2.3 billion. However, recent forecasts suggest a slightly more optimistic EPS of $1.38, representing an 11.3% year-over-year growth. This anticipated increase is supported by a 4.6% rise in revenues, expected to hit $2.31 billion for the quarter ending December 2024.

Despite a minor downward revision of 1.1% in the consensus EPS estimate over the past 30 days, the outlook for Zoetis remains positive. This trend in estimate revisions is crucial as it often mirrors short-term stock price movements, potentially affecting investor sentiment. The Zacks Consensus Estimate is in line with the higher EPS prediction of $1.38, reflecting confidence in Zoetis's ability to meet or surpass expectations.

Key financial metrics shed light on Zoetis's market valuation. The company's price-to-earnings (P/E) ratio is 32.48, showcasing how the market values its earnings. Its price-to-sales ratio stands at 8.59, with an enterprise value to sales ratio of 9.14, indicating the market's valuation in relation to its sales. Furthermore, the enterprise value to operating cash flow ratio is 28.41, emphasizing the company's valuation concerning its operational cash flow.

Zoetis's financial health is underscored by an earnings yield of 3.08% and a debt-to-equity ratio of 1.29, demonstrating a balanced approach to financing its assets. The company's current ratio of 3.69 indicates a robust ability to cover short-term liabilities with short-term assets, highlighting its strong financial position. As the earnings report date approaches, these metrics will be under close scrutiny by investors and analysts.

• Zoetis Inc. (NYSE:ZTS) is expected to report an EPS of $1.38, marking an 11.3% increase from the previous year.
• Projected revenues for the quarter ending December 2024 are estimated to reach $2.31 billion, a 4.6% rise.
• The company's P/E ratio stands at 32.48, with a debt-to-equity ratio of 1.29, indicating a solid financial position ahead of its earnings report.

Zoetis Inc. (NYSE:ZTS), a leading global animal health company, is gearing up to release its quarterly earnings on February 13, 2025, before the market opens. As a significant player in the veterinary vaccines and medicines sector, Zoetis competes with industry giants like Elanco Animal Health and Merck Animal Health.

Wall Street analysts have set the bar with an earnings per share (EPS) estimate of $1.37 for Zoetis, alongside projected revenues of approximately $2.3 billion. However, recent forecasts suggest a slightly more optimistic EPS of $1.38, representing an 11.3% year-over-year growth. This anticipated increase is supported by a 4.6% rise in revenues, expected to hit $2.31 billion for the quarter ending December 2024.

Despite a minor downward revision of 1.1% in the consensus EPS estimate over the past 30 days, the outlook for Zoetis remains positive. This trend in estimate revisions is crucial as it often mirrors short-term stock price movements, potentially affecting investor sentiment. The Zacks Consensus Estimate is in line with the higher EPS prediction of $1.38, reflecting confidence in Zoetis's ability to meet or surpass expectations.

Key financial metrics shed light on Zoetis's market valuation. The company's price-to-earnings (P/E) ratio is 32.48, showcasing how the market values its earnings. Its price-to-sales ratio stands at 8.59, with an enterprise value to sales ratio of 9.14, indicating the market's valuation in relation to its sales. Furthermore, the enterprise value to operating cash flow ratio is 28.41, emphasizing the company's valuation concerning its operational cash flow.

Zoetis's financial health is underscored by an earnings yield of 3.08% and a debt-to-equity ratio of 1.29, demonstrating a balanced approach to financing its assets. The company's current ratio of 3.69 indicates a robust ability to cover short-term liabilities with short-term assets, highlighting its strong financial position. As the earnings report date approaches, these metrics will be under close scrutiny by investors and analysts.